Related Experiment Video
Updated: Sep 5, 2025

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Genotype-phenotype correlations in CPT1A deficiency detected by newborn screening in Pacific populations
Isaac Bernhardt1, Emma Glamuzina1, Leah K Dowsett2,3
1National Metabolic Service Auckland City Hospital and Starship Children's Hospital Auckland New Zealand.
Insights
Carnitine palmitoyltransferase 1A (CPT1A) deficiency diagnosis has increased with expanded metabolic screening. This study identifies two new CPT1A variants in Micronesian and Niuean populations, highlighting genotype-phenotype correlations for improved newborn screening and patient care.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a rare genetic disorder affecting long-chain fatty acid oxidation.
- Expanded metabolic screening (EMS) has increased CPT1A deficiency detection rates in newborn populations.
- Pacific Islander populations, including Micronesians and Niueans, are increasingly recognized in metabolic screening contexts.
Purpose of the Study:
- To identify and characterize novel CPT1A variants in Micronesian and Niuean populations.
- To investigate the genotype-phenotype correlations of these variants.
- To inform newborn screening protocols and clinical management for these populations.
Main Methods:
- Genetic analysis of individuals with CPT1A deficiency from Micronesian and Niuean ancestries.
- Enzyme activity assays using cultured skin fibroblasts.
- Clinical data review for metabolic decompensation and presentation.
Main Results:
- A novel CPT1A c.100T>C (p.S34P) variant was identified in 22 Micronesian individuals, with residual enzyme activity of 26% and no clinical decompensation.
- A CPT1A c.2122A>C (p.S708R) variant was found in three Niuean individuals, exhibiting severe enzyme deficiency (4% activity) and classic CPT1A deficiency symptoms.
- Asymptomatic adults homozygous for the Micronesian variant were identified through family screening.
Conclusions:
- The study identified two distinct CPT1A variants in Pacific Islander populations, with varying clinical presentations and enzyme activities.
- Understanding these genotype-phenotype correlations is crucial for accurate diagnosis and management of CPT1A deficiency detected through newborn screening.
- Increased migration may lead to a higher prevalence of these variants in global metabolic services, necessitating awareness and tailored approaches.
Abstract:
Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a long chain fatty acid oxidation disorder, typically presenting with hypoketotic hypoglycaemia and liver dysfunction during fasting and intercurrent illness. Classical CPT1A deficiency is a rare disease, although a milder 'Arctic variant' (p.P479L) is common in the Inuit population. Since the introduction of expanded metabolic screening (EMS), the newborn screening programmes of Hawai'i and New Zealand (NZ) have detected a significant increase in the incidence of CPT1A deficiency. We report 22 individuals of Micronesian descent (12 in NZ and 10 in Hawai'i), homozygous for a CPT1A c.100T>C (p.S34P) variant detected by EMS or ascertained following diagnosis of a family member. No individuals with the Micronesian variant presented clinically with metabolic decompensation prior to diagnosis or during follow-up. Three asymptomatic homozygous adults were detected following the diagnosis of their children by EMS. CPT1A activity in cultured skin fibroblasts showed residual enzyme activity of 26% of normal controls. Secondly, we report three individuals from two unrelated Niuean families who presented clinically with symptoms of classic CPT1A deficiency, prior to the introduction of EMS. All were found to be homozygous for a CPT1A c.2122A>C (p.S708R) variant. CPT1A activity in fibroblasts of all three individuals was severely reduced at 4% of normal controls. Migration pressure, in part due to climate change may lead to increased frequency of presentation of Pacific peoples to regional metabolic services around the world. Knowledge of genotype-phenotype correlations in these populations will therefore inform counselling and treatment of those detected by newborn screening.
More Related Videos
06:41In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Pleiotropy
Incomplete Dominance
Pedigree Analysis
Genetic Lingo
Background and Environment Affect Phenotype
An example of how genetic background affects phenotype can be seen in horses. The Extension gene in horses is responsible for their coat color. A wild-type gene (EE) produces black pigment in the coat, while a mutant gene (ee) produces red pigment. A...
Epistasis Analysis